Premium
New anticonvulsant drugs and the role of clobazam as adjunctive therapy
Author(s) -
Trimble Michael
Publication year - 1995
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470100706
Subject(s) - clobazam , lamotrigine , gabapentin , medicine , anticonvulsant , vigabatrin , medical prescription , epilepsy , pharmacology , intensive care medicine , psychiatry , alternative medicine , pathology
Abstract In this paper, consideration to the present state of anticonvulsant therapy with the new drugs is presented by six international experts. Arguments both for and against polytherapy are given, and a summary of the pharmacokinetic interactions that occur with and among the new drugs is made. The concept of rational combination therapy is discussed. Special consideration is then given to the current place for clobazam, gabapentin, lamotrigine and vigabatrin in the management of epilepsy, and the results of several new trials with these various drugs are given. While it is too early to clarify the exact clinical profiles of these compounds, the place for these drugs, and the patient groups that might most benefit from their prescription are presented. With regards to clobazam, new data on long term efficacy are reported, noting a low frequency of the development of tolerance, and freedom from seizures in up to 10 per cent of patients when given as adjunctive therapy.